enGene (NASDAQ:ENGN) Now Covered by HC Wainwright

Equities researchers at HC Wainwright started coverage on shares of enGene (NASDAQ:ENGN) in a report released on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $25.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 328.82% from the company’s current price.

Other analysts have also recently issued reports about the company. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research report on Friday, December 6th. Citizens Jmp raised enGene to a “strong-buy” rating in a report on Monday, November 18th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Raymond James initiated coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, enGene currently has a consensus rating of “Buy” and a consensus target price of $29.78.

enGene Stock Performance

Shares of enGene stock opened at $5.83 on Monday. The stock has a market capitalization of $257.78 million, a price-to-earnings ratio of -10.05 and a beta of -0.78. The firm’s fifty day simple moving average is $8.13 and its 200-day simple moving average is $7.80. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. enGene has a 12 month low of $4.42 and a 12 month high of $18.40.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. As a group, equities analysts forecast that enGene will post -1.52 earnings per share for the current year.

Insider Buying and Selling

In other enGene news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the transaction, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth Opportunities F. Forbion bought 341,332 shares of the company’s stock in a transaction on Monday, September 30th. The shares were acquired at an average price of $6.34 per share, with a total value of $2,164,044.88. Following the completion of the acquisition, the insider now directly owns 2,400,791 shares in the company, valued at $15,221,014.94. This represents a 16.57 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 420,965 shares of company stock worth $2,651,103 in the last quarter. Company insiders own 13.70% of the company’s stock.

Institutional Investors Weigh In On enGene

A number of institutional investors and hedge funds have recently bought and sold shares of ENGN. SR One Capital Management LP acquired a new position in shares of enGene in the second quarter worth $4,715,000. Logos Global Management LP grew its holdings in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares in the last quarter. Wolverine Asset Management LLC acquired a new position in shares of enGene in the third quarter valued at approximately $37,000. Point72 Asset Management L.P. lifted its stake in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares during the period. Finally, Franklin Resources Inc. boosted its position in enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.